Kyoto University · Biochemistry, Genetics and Molecular Biology
Shinya Yamanaka 교수의 연구실은 체세포를 난세포와 유사한 만능세포로 재프로그래밍하는 인도스티튜드 플루리포텐트 스템 세포(iPS 세포)의 기반 기전을 규명하고 있습니다. 특히 바이러스를 사용하지 않는 비유전자 삽입 방법을 개발해, 암성 위험을 줄인 환자 특화 치료용 세포를 만드는 데 초점을 맞추고 있습니다. 또한 다양한 종류의 체세포에서 iPS 세포를 유도하고, 그 세포의 기원과 분화 능력을 정밀하게 분석함으로써 재생의학과 약물 개발의 새로운 길을 열고 있습니다.
Figures are computed from collected data and may differ slightly.
Induced pluripotent stem (iPS) cells have been generated from mouse and human somatic cells by introducing Oct3/4 and Sox2 with either Klf4 and c-Myc or Nanog and Lin28 using retroviruses or lentiviruses. Patient-specific iPS cells could be useful in drug discovery and regenerative medicine. However, viral integration into the host genome increases the risk of tumorigenicity. Here, we report the generation of mouse iPS cells without viral vectors. Repeated transfection of two expression plasmids
Induced pluripotent stem (iPS) cells have been generated from mouse and human fibroblasts by the retroviral transduction of four transcription factors. However, the cell origins and molecular mechanisms of iPS cell induction remain elusive. This report describes the generation of iPS cells from adult mouse hepatocytes and gastric epithelial cells. These iPS cell clones appear to be equivalent to embryonic stem cells in gene expression and are competent to generate germline chimeras. Genetic line
Open papers in the app to read, cite, and organize with AI.
